

# UC Irvine

## UC Irvine Previously Published Works

### Title

Hemodialysis Disparities in African Americans: The Deeply Integrated Concept of Race in the Social Fabric of Our Society

### Permalink

<https://escholarship.org/uc/item/4sq6k89p>

### Journal

Seminars in Dialysis, 30(3)

### ISSN

0894-0959

### Authors

Norris, Keith C  
Williams, Sandra F  
Rhee, Connie M  
et al.

### Publication Date

2017-05-01

### DOI

10.1111/sdi.12589

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



Published in final edited form as:

*Semin Dial.* 2017 May ; 30(3): 213–223. doi:10.1111/sdi.12589.

## Hemodialysis Disparities in African Americans: The Deeply Integrated Concept of Race in the Social Fabric of our Society

Keith C. Norris<sup>1</sup>, Sandra F. Williams<sup>2</sup>, Connie M. Rhee<sup>3</sup>, Susanne B. Nicholas<sup>1</sup>, Csaba P. Kovesdy<sup>4,5</sup>, Kamyar Kalantar-Zadeh<sup>3</sup>, and L. Ebony Boulware<sup>6</sup>

<sup>1</sup>Department of Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California

<sup>2</sup>Department of Integrated Medical Science, Florida Atlantic University, Florida

<sup>3</sup>Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine, Orange, California

<sup>4</sup>Nephrology Section, Memphis VA Medical Center, Memphis, Tennessee

<sup>5</sup>Division of Nephrology, University of Tennessee Health Science Center, Memphis, Tennessee

<sup>6</sup>Department of Medicine, Duke University, Durham, North Carolina

### Abstract

End-stage renal disease (ESRD) is one of the starkest examples of racial/ethnic disparities in health. Racial/ethnic minorities are 1.5 to nearly 4 times more likely than their non-Hispanic White counterparts to require renal replacement therapy (RRT), with African Americans suffering from the highest rates of ESRD. Despite improvements over the last 25 years, substantial racial differences persistence in dialysis quality measures such as RRT modality options, dialysis adequacy, anemia, mineral and bone disease, vascular access, and pre-ESRD care. This report will outline the current status of racial disparities in key ESRD quality measures and explore the impact of race. While the term race represents a social construct, its association with health is more complex. Multiple individual and community level social determinants of health are defined by the social positioning of race in the U.S., while biologic differences may reflect distinct epigenetic changes and linkages to ancestral geographic origins. Together these factors conspire to influence dialysis outcomes among African Americans with ESRD.

### Keywords

Race; disparities; dialysis; end-stage renal disease; African American; Black; social determinants

---

“Few people are capable of expressing with equanimity opinions which differ from the prejudices of their social environment.” – Albert Einstein

---

**Address for Correspondence:** Keith C. Norris, MD, PhD, 911 Broxton Ave., Suite 103, Los Angeles, CA 90024, Phone 310-794-6973, Fax 310-794-0732, kcnorris@mednet.ucla.edu.

**Financial Disclosures:**

None of the other authors declare any relevant conflicts of interest.

Multiple aspects pertaining to end-stage renal disease (ESRD) are among the starkest examples of the disparities which exist between healthcare delivered to racial/ethnic minorities and that delivered to non-minority populations in the United States (US).(1, 2) This is reflected in part by the incidence rate of ESRD which affects US minorities from 1.5 to nearly 4.0 times more than age-adjusted non-Hispanic White counterparts, with African Americans (or Blacks) suffering from the highest rates.(3, 4) There is also extensive data outlining racial differences in ESRD quality measures such as renal replacement therapy (RRT) modality options, dialysis adequacy, anemia, mineral and bone disease (MBD), vascular access, pre-ESRD care and hospitalizations. This report will outline the current status of racial disparities in key ESRD quality measures and explore the potential impact of race as primarily a social determinant of health with a lesser contribution from biologic differences that conspire to influence health outcomes among African Americans with ESRD. There will also be a discussion of the impact of race at the community level that affects ESRD outcomes.

The elimination of racial and ethnic disparities in all stages of CKD is becoming widely recognized in the field of nephrology as an important initiative to improve overall patient outcomes,(1, 5–7) and is a highlighted target for Healthy People 2020, our nation’s blueprint for health.(8) The earlier recognition of increased rates of ESRD among African Americans in the late 1970s and early 1980s(9–11) spawned interest in ESRD disparities in the early 1990’s(12, 13) and underscored the need to better understand the issues underlying both ESRD incidence and quality of care for racial/ethnic minorities, women and other disadvantaged groups receiving RRT.(13–15) In response to these earlier findings over two decades ago national ESRD performance measures and quality standards were introduced which led to a substantial reduction in dialysis-related disparities and to progressive improvement in the quality of care for all dialysis patients;(16, 17) however, much work remains.

In evaluating kidney disease-related racial disparities it is critical that we concurrently view this topic through two distinctly different lenses, one viewing race as a social construct and one as select biological differences. Thus, the role of social determinants of health juxtaposed with an array of geo-evolutionary risk and resilience genes may conspire differently in varying settings to influence outcomes for patients along the spectrum of chronic kidney disease (CKD). It is important that the nephrology community have an in-depth understanding of both the present state of affairs in regards to the quality of pre-ESRD and ESRD care for patients on dialysis and an appreciation of how socio-cultural and biologic implications of race influence clinical outcomes. Through this understanding, we can move closer to creating more effective solutions to eliminate disparities.

## ESRD Treatment Modalities

Despite a similar prevalence of the early stages of CKD, African Americans are 3–4 times more likely than their non-Hispanic White counterparts to progress to ESRD and require RRT.(3, 4) In the U.S. the preferred options of RRT are kidney transplantation or home dialysis, with in-center hemodialysis being less desirable (although remaining the most common form of RRT).(18) Yet, Black ESRD patients are less likely to receive RRT with

either a kidney transplant or home dialysis therapy. In 1991 compared with White patients with ESRD, Black patients with ESRD were 42% less likely to have a functioning kidney transplant, 28% less likely to be treated with peritoneal dialysis and 45% less likely to be treated with home hemodialysis.(19)

These disparities in ESRD treatment modalities have changed very little over the last 20 years. In 2016 Mehrotra et al. reported in an adjusted analysis of over 160,000 patients who initiated maintenance dialysis within a single large dialysis organization, and found that compared to Whites, African Americans were still 60% less likely to be treated with home hemodialysis and 47% less likely to be treated with peritoneal dialysis. These findings highlight the need for continued efforts to achieve greater equity in the use of the preferred options for ESRD care among African Americans.

## Dialysis Adequacy

Large racial disparities in dialysis adequacy were also noted over twenty years ago when Frankenfield et al. reported that compared to Whites, African Americans were 40% more likely to have suboptimal dialysis adequacy as defined by a  $Kt/V < 1.2$ .(20) Fortunately there has been a major reduction in the racial disparities of dialysis adequacy following a national effort in 1994 spearheaded by the Health Care Financing Administration (now Centers for Medicare & Medicaid Services or CMS) ESRD Health Care Quality Improvement Program (HCQIP) to improve the quality of ESRD care.(17, 21, 22)

This approach which included the mandatory facility reporting of dialysis quality of care metrics was further reinforced in the mid 1990s' by the CMS ESRD Continuous Performance Measures (CPM)(23) based on the National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines.(24) These programs have concurrently advanced equity in the treatment of dialysis patients through physician accountability and eliminated the need for initiating race-based interventions to address disparities in dialysis adequacy.(17)

As a result of these initiatives, data from a 2015 report of  $Kt/V$  for patients on dialysis for at least 1 year who underwent dialysis 3 times per week found a mean  $Kt/V$  of 1.6 for non-blacks and 1.5 for Blacks in 2010 and a mean  $Kt/V$  1.6 for both in 2011.(25) While the CMS ESRD CPM and ongoing quality improvement measures have eliminated dialysis adequacy-related racial disparities on an individual level, disparities have recently been reported at the facility level with a lower level of dialysis adequacy reported in patients treated in dialysis facilities within neighborhoods with a higher proportion of African Americans. This inequity persists even after controlling for neighborhood socioeconomic status and other factors in some,(26) but not all studies(27). Findings such as these reinforce the need to better understand and further explore the driving factors for disparities at individual and particularly at facility/community levels in order to further advance efforts to achieve equity in treatment adequacy at dialysis facilities regardless of location or patient case-mix.

## Anemia

Twenty years ago, at the time of the introduction of CMS performance measures, compared to White prevalent hemodialysis (HD) patients, African American prevalent HD patients were 20% more likely to have serum hemoglobin (Hb) levels < 10g/dl, the lowest recommended level for dialysis patients.(20) What has not been commonly appreciated is that in the general(28) and early CKD populations African Americans have approximately 0.5g/dl lower adjusted mean Hb levels than Whites.(29, 30) This may be due not only to nutritional deficiencies but to variant hemoglobin phenotypes(31, 32) and/or higher rates of inflammation.(33) Therefore, not unexpectedly, African Americans have both lower Hb levels at the initiation of dialysis (9.3 g/dl compared to 9.7 g/dl for White patients(3)), as well as greater requirements of erythropoiesis-stimulating agents (ESAs) to achieve similar target Hb levels on maintenance hemodialysis.(31, 34)

Since the implementation of the KDOQI initiative and the CMS CPM program in the 1990's,(17) there has been a dramatic improvement in the percent of African American patients on RRT who have achieved target Hb levels. There had been concern that any positive impact resulting from these initiatives would have been negated by the implementation of the 2011 Medicare ESRD prospective payment system (PPS) and the simultaneous FDA-mandated manufacturer label changes to lower recommended Hb targets, each of which could have led to more restricted ESA use, increased rates of anemia and subsequently worse outcomes.(35, 36) This had been of particular concern for Black patients given the historically higher ESA use needed to maintain parity in Hb levels. But a 2015 report of over 7000 maintenance hemodialysis patients at 132 facilities from the Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor by Turenne et al., found that, while overall mean Hb levels fell from 11.5 to 11.0 g/dl and mean EPO dose declined from 20,506 to 14,777 U/wk, no meaningful differences by race were observed.(25)

An interesting analysis by Wang et al, was also completed following the PPS and ESA labeling changes in 2011. They found no difference in cardiovascular outcomes among White fee-for-service Medicare patients on dialysis 66 years or older during the two year period before and after the PPS and ESA changes while an 18% reduction in cardiovascular events was observed in Black patients. Such findings suggest that different target ESA and Hb levels may be appropriate for Black dialysis patients.(37)

Thus, while anemia management and regulatory practices have changed significantly over time, there has been no evidence of any resulting anemia-related racial disparities among individual patients,(25) with the one possible exception of improved cardiovascular outcomes for Black patients.(37) One study did suggest that anemia-related disparities still persist at a facility level, reflected in a lower rate of achievement of targeted Hb levels in patients treated in facilities in neighborhoods with a higher proportion of African Americans.(26) Interestingly, when facility level Hb targets are examined by the percentage of African Americans patients per facility (rather than by neighborhood) there was no influence on anemia related quality measures.(27) This highlights the likely importance of social determinants at a community level. The factors influencing the persisting anemia disparities in African American dominant neighborhoods, and the finding of decreased

mortality rates among African Americans with lower ESA use and lower Hb targets need to be further explored.

## Mineral and Bone Disorders (MBD)

Recommended targets for intact parathyroid hormone (iPTH) levels in patients with CKD were established by the 2003 report of the K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease(38) and subsequently implemented as part of the CMS dialysis quality measures. Achievement of recommended targets has been less successful among African Americans, compared to Whites, likely secondary to African Americans' lower baseline 25(OH)D levels and higher iPTH levels with or without renal dysfunction. Blacks with ESRD consistently require higher and more frequent doses of activated vitamin D and cinacalcet.(25) This persisting disparity was reported in 2010 by Kalantar et al, approximately 15 years after introduction of the CMS measures, when 139,328 thrice-weekly treated hemodialysis patients (32% Black) were evaluated for up to 60 months and Black patients were found to have higher iPTH and calcium levels compared to non-Blacks, while serum phosphate and alkaline phosphate levels did not differ.(39) Blacks with advanced CKD(40) and ESRD(41, 42) also have lower levels of fibroblast growth factor 23 (FGF-23), another important contributor to mineral metabolism and clinical outcomes in renal disease.

These disparate findings regarding MBD risk factors, may however be associated with both positive and negative health consequences. While hypovitaminosis D has emerged as a potential independent risk factor for all-cause and cardiovascular mortality,(43) a 1999 report noted that in the presence of increased iPTH levels there was increased bone mineral density among African American compared to White dialysis patients,(44) while a 2000 report noted reduced fracture rates among Black dialysis patients,(45) an observation that persists.(46, 47) Also higher levels of iPTH in Blacks with ESRD leads to an increased incidence of hyperparathyroid bone disease in contrast to their White peers who may be at increased risk for the perhaps equally serious condition of adynamic bone disease due to lower iPTH levels.(48, 49) Most significantly, both Wolf and colleagues and Kalantar et al. found that among different dialysis cohorts there was a demonstrably greater likelihood for survival in Black dialysis patients who received higher doses of activated vitamin D compared with those who either received lower doses or no active vitamin D, while survival in White patients did not significantly vary with paricalcitol use.(39, 49)

Lower FGF-23 levels appear to impart an added survival advantage to Blacks patients on dialysis.(41) A stratified analysis of mortality by FGF-23 levels and race in 400 dialysis patients revealed a 60% lower risk of death in Black versus White patients in the cohort below the population median of FGF-23 levels while there was no Black-White mortality difference in the cohort above the population median.(41) Following the implementation of 2011 cost-saving measures by the Medicare ESRD PPS Turenne et al. reported mean serum iPTH increased from 340 to 435 pg/ml, but found no meaningful differences by race.(25)

In sum, these findings suggest that MBD and the effects of their treatment may differ between Blacks and Whites, and may partly account for the observed differences in survival

between Black and White hemodialysis patients. Whether these differences in morbidity and mortality seen in African Americans are a consequence of the intrinsic baseline differences in indices of bone and mineral metabolism or due to the resultant more aggressive indicated treatment, requires further analysis to elucidate these Black-White MBD related differences in ESRD patients.

## Vascular Access

While superior clinical outcomes have long been established for patients who begin hemodialysis treatment with a working arteriovenous fistula (AVF), starting hemodialysis with a functioning vascular access remains one of the major lingering areas of racial and gender disparities in the dialysis population.(50, 51) Despite the early KDOQI Vascular Access Guidelines recommending targeting fistula rates of 40% or greater for incident dialysis patients,(52) and more recent guidelines targeting even higher rates,(53) significant disparities persist.

In a 2015 analysis of over 650,000 patients initiating hemodialysis, Nee et al. found African Americans were still significantly less likely to have an AVF even after adjusting for clinical and socioeconomic factors including insurance status and neighborhood poverty.(54) Likewise, in a cohort of nearly 400,000 patients in the United States Renal Data System (USRDS), Zarkowsky and colleagues also found in 2015 that Black patients and Hispanic patients continued to initiate hemodialysis with an AVF less frequently than non-Hispanic White patients, despite being younger and having fewer comorbidities, regardless of insurance status.(55) When the analysis stratified Black patients based on either insurance status or whether they had been followed by a nephrologist for over a year prior to the initiation of HD, they were respectively 10% and 19% less likely to start HD with an AVF compared to their non-Hispanic White peers.(55) The strong association between Black race and lower AVF placement also continues to be seen in older ESRD populations who frequently are covered by Medicare insurance,(50) and persists after adjustments for multiple clinical and socioeconomic factors.(50, 54–56) This therefore represents yet another parameter that begs further evaluation to elucidate possible solutions to eliminate these disparities.

## Pre-ESRD Nephrologist Care

Pre-ESRD care is linked to several other ESRD quality care indicators such as anemia and vascular access, and the lack of or delay in establishing pre-ESRD care is associated with increased risk of death following transition to RRT.(57–59) Unfortunately there has been little change over the last 15–20 years in the higher rate of delayed or no pre-ESRD nephrology care for Black patients compared to Whites.(57–61) Despite the introduction of the ESRD quality care initiatives in the early 1990s, a 2015 report from Gillespie and colleagues found that at baseline African Americans were still less likely than Whites to have received any pre-ESRD care (31% vs. 38%), and less likely to have seen a nephrologist more than 12 months prior to initiating dialysis (24% vs. 30%).(58) Further, after multiple statistical adjustments including insurance coverage and region of care, African Americans

were 34% less likely than Whites to have >12 months of pre-ESRD nephrology care versus no care.(58)

These findings are reinforced by an analysis of interstate variation in nephrologist pre-ESRD care for nearly 375,000 adult USRDS patients that found the average state-level probability of having received nephrologist care 12 months prior to dialysis was lower in Blacks, especially in the younger Black subpopulation,(62) and attenuated for older Blacks, who were more likely to have Medicare insurance coverage prior to RRT.(62) This highlights insurance as a major driver for racial disparities in the pre-ESRD period, although not the sole influence as the disparities persisted even after adjusting for differences in insurance coverage. Therefore, like vascular access, further investigation into any potential underlying factors that could account for these disparities such as medical mistrust, health literacy, provider and patient biases, health system barriers, social determinants and others should be pursued.(6, 55, 63–65)

### Survival for African Americans on Dialysis

Despite the outlined inequities in the quality of ESRD care, epidemiologic data have consistently shown that various racial and ethnic minorities treated with dialysis have greater survival rates than their peer majority groups even after adjusting for transplantation.(66–75) The observation that minority racial/ethnic groups on dialysis have greater survival than their majority peers is not limited to the U.S, but has also reported elsewhere including Israel and Denmark.(71, 73, 76) In the U.S. the Black-White survival difference appears to vary by age as there are significantly better survival rates for Blacks above 40 or 50 years of age compared to Whites, but younger Black and White patients have similar survival rates.(67, 68, 70)

Our understanding of the impact of community characteristics on survival in dialysis patients is more limited. When Kalbfleisch et al. computed standardized mortality ratios (SMRs) for patient race in nearly 6000 U.S. dialysis facilities without adjustment, it was found that facilities with higher proportions of Black patients had better survival outcomes.(77) However, after adjusting for racial differences within each facility, facilities with higher proportions of Black patients had poorer survival outcomes among both Black and non-Black patients.(77) This trend was corroborated by Hall et al. who also found that dialysis facilities treating predominantly racial/ethnic minority patients exhibited worse than expected patient survival.(27) Further, dialysis facilities located in neighborhoods with a higher proportion of African American residents were also found to have worse survival rates.(26, 78, 79)

These findings indicate that although Black race may confer a better survival rate on dialysis at an individual level, this survival benefit could be dissipated by receiving dialysis care at a facility which either treats predominantly minority patients or is located in a community with predominantly minority residents. This highlights the powerful moderating effect of socioeconomic status and contextual influences (i.e., practice patterns and community/environmental resources). Indeed, when we examined all cause mortality by race/ethnicity of patients with equal access to care in the U.S. veterans health system we found increased



adjusted survival rates for African Americans compared to their White peers, in contrast to lower adjusted survival rates reported in the general population.(80, 81) What accounts for the survival benefits of Blacks on dialysis or the inequities in ESRD and pre-ESRD care is unclear, but these findings of the intertwined social and economic influences have important implications for patient outcomes as well as the CMS rating of facility outcomes.

## DEFINING RACE

While the concept of race is deeply integrated into the social fabric of our society, there is no generally agreed upon definition for the term. DNA analyses suggest there are no distinct, discrete, identifiable populations by race in modern *Homo sapiens*.(82) The term race carries complex nuances that reflect culture, history, socioeconomics, and political status, juxtaposed with differing frequencies of particular genetic variants that reflect important linkages to ancestral geographic origins.(83) Thus, while race is not a defined biologic entity, it is not strictly true that race has no biological connection.(83)

The current categorization system of race derives from four major subsets of humans originally proposed by Francis Bernier in 1684,(84) and subsequently configured into a more socially-constructed hierarchal set of groupings by Carl Linnaeus in the 1700s in his treatise, *Systema Naturae*.(85) Linnaeus associated select personality traits, skills, and abilities,(85) to the four racial categories (European, Native American, Asian, and African) establishing a perceived “scientific” foundation that race is the primary determinant of human traits and capacities, and implying that there may be an inherent superiority of a particular group”.(86) These original racial designations differ little from the major racial groups used today by the U.S. Office of Management and Budget (OMB), the department which governs census reporting, and include the original categories -White, American Indian or Alaska Native, Asian, and Black or African American - with a fifth category, Native Hawaiian or Other Pacific Islander added in 2000.(87–89) The OMB has also added two major ethnic categories for each person, Hispanic or Latino, and not Hispanic or Latino.(87, 88) Similar to race, the categorization of ethnicity was founded on socio-cultural and linguistic characteristics, and has no solid scientific basis,(90, 91) although select ancestral biologic linkages may exist. It is important to mention that these designations are embedded in a European world-view and the norms that follow through that lens would likely differ if viewed through another cultural lens.

Therefore it is not surprising that health outcomes stratified by race and ethnicity are less likely a result of biology and more strongly influenced by one’s social position and the associated socio-ecologic determinants of health such as: discrimination, residential segregation,(92) educational and income inequalities,(93–96) imbalance in community level assets, access to care,(5) health care resources,(78, 97, 98) and exposure to environmental toxins.(6, 99) Additional factors include health system barriers, unconscious provider bias, stereotype threat, medical mistrust, and patient beliefs and behaviors.(63, 65, 100, 101) Stereotype threat is a more recently recognized concept in healthcare and refers to the fear of being judged by, and/or of personally confirming through one’s own actions, negative group stereotypes that operate within the domain of healthcare, including inferior intelligence,

lower status, greater likelihood of engaging in risky behaviors, and being less deserving of the highest standard of care.(101)

Thus the term “race” and its influence on health outcomes seems to most accurately represent a collection of people organized around shared ancestry and history, shared cultural norms and language, and social identity as well as shared biological characteristics driven by epigenetic changes and/or geo-evolutionary pressures that have led to differing prevalences of select gene polymorphisms (Figure 1).(83, 102, 103) This socio-biologic construct may allow us to more accurately characterize and explore the many factors which account for the disparities in ESRD parameters and measured targets.

## Discussion

Both social and biological factors appear to contribute to the more frequent need for RRT for African Americans where access to and quality of care, patient behaviors, control of risk factor conditions and others combine with CKD risk alleles to have major influences on CKD development and progression.(2, 63) Once progression to ESRD has occurred, the impact of the dual roles of social and biologic factors may vary substantially for different quality measures and outcomes.

The impact of social positioning by race and associated financial and sociocultural barriers appear to heavily influence persistent disparities in the likelihood of receiving different forms of RRT, pre-ESRD care and AVF placement.(1, 5, 6),(64, 93, 97) In terms of finances, inadequate health insurance and other access barriers to care are likely to contribute substantially to African American patients’ less frequent receipt of pre-ESRD care, reduced access to vascular surgery and therefore less timely AVF placement and maturation, more frequent inadequate home and/or social support or difficulties navigating the complex multi-disciplinary protocols required to transition to home dialysis modalities or attain a renal transplant.(104–106) Further, sociocultural factors such as unconscious provider biases may result in differential clinical practice decision-making, while medical distrust and related factors influence patients’ beliefs and behaviors further reducing African Americans’ likelihood to receive appropriate care and achieve equitable clinical outcomes.(63, 107)

By contrast, biologic variations related to ancestral polymorphisms appear to also influence disparities in CKD risk and ESRD treatment and outcomes. The effort to understand potential biologic underpinnings of CKD has led to the recognition of increased prevalence of sickle cell disease/trait(108) and select Apolipoprotein L-1 (APOL 1) alleles as CKD risk factors in persons of African descent,(109, 110) while oxidative protective alleles (e.g. glutathione-S-transferase-m1 or GSTM1)(111) and others,(112) have been identified as potential resilience factors.

Further, genetic factors such as differing distribution of melanin and vitamin D binding protein polymorphisms(113, 114) may help explain the racial differences noted in the vitamin D-PTH axis which likely contribute to disparities in the incidence of MBD and associated outcomes among different racial groups affected by ESRD. Similarly Hb variants may contribute to disparities in anemia management, including the need for higher doses of

therapy and therefore increased costs to achieve recommended goals. There also is evidence that worse AVF placement outcomes may be related to the potential adverse impact of higher ESA dosing or gene polymorphisms on AVF maturation,(115) and/or racial differences in vascular anatomy.(116)

Factors which underlie the surprising finding that African Americans on dialysis have better adjusted survival rates than Whites,(69, 72, 117) remain incompletely explained and raise important questions about possible mechanism(s). Reasons for this observation may include survival bias which refers to variations in the health of Blacks and Whites who survive to dialysis; psychosocial resilience; and permissive or effect-modifying biologic related resilience that may be expressed in a chronic disease state such as dialysis.(69, 98, 112, 118, 119) This enhanced survival on dialysis, however, does not extend to younger Black patients, which may reflect higher rates of homicide, motor vehicle accident, suicide, drug overdose and/or other community level factors.(69, 117, 120) Findings of attenuation of the survival bias among patients receiving care in low resource neighborhoods draw continued attention to the seemingly substantial contribution of contextual social determinants on the health of African American dialysis patients. Our task is to exploit those factors influencing disparities to create effective interventions and policies to achieve the goal of health equity for all patients.

## Implications for ESRD Policy

The overwhelming impact of race as a dual social construct and as a marker of biologic ancestral diversity on the health of patients on dialysis cannot be ignored in creating effective solutions. Importantly, as we identify disparities and/or differences between racial groups, the lessons learned should lead not only to new biomedical advances including personalized medicine but also to new social and health policy changes that will improve outcomes for all populations.(121, 122) In addition to policies funding research to identify targeted approaches to improve treatment, health policies are critical to address access to, and quality of, care and community social care factors as health is heavily influenced by where people live, labor, learn, play, and pray.(123)

There are numerous potential unintended adverse consequences related to current efforts to regulate the quality of dialysis treatment. Section 153(c) of the Medicare Improvements for Patients and Providers Act (MIPPA) of 2008 directs the Secretary of Health and Human Services (HHS) to develop a method to assess the quality of dialysis care provided by facilities and to link this performance to payment. Facilities which fail to meet this performance standard may receive a payment reduction of up to two percent.(124) While many ESRD quality measures have improved for African Americans compared to 20 years ago due to improved regulation, many still lag behind measures for non-Hispanic Whites, especially when viewed on a facility or neighborhood level.(26, 78, 79) Reimbursement based on facility level performance raises concerns that facilities in low-income communities, often comprised of a disproportionately high percentage of racial/ethnic minorities, may be adversely affected.(125) Such reimbursement policies could lead to selective removal of patients from facilities (cherry picking), depriving minority patients of the best quality care. Large dialysis organizations could also elect to not locate facilities in

low income and predominately Black neighborhoods further compromising access to dialysis care. Confounding these concerns is the fact that the cost of care for long-term dialysis patients by race is nearly 10% greater for African Americans (cost for anemia and MBD medications) after accounting for other factors.(126) The pay for performance policy adopted by CMS therefore has the potential to adversely affect the delivery of care to certain populations, especially in facilities treating high percentages of Black patients that must balance higher costs, less favorable insurance mix, and worse clinical outcomes leading to a greater likelihood of a facility being penalized. Inclusion of self-reported or neighborhood race into a PPS should be considered,(126) but may require a better understanding of known biological differences such as MBD and anemia outcomes, and modeling of the social effects that influence neighborhoods.

## Conclusion

The root causes of dialysis related racial disparities are complex, and stem from race being not only an indicator of sociocultural status but also a proxy for ancestral biologic variation. Thus there are two broad lenses through which racial disparities may be viewed. Efforts to attribute disparities in quality metrics and clinical outcomes should directly address which aspects of race (i.e., social or ancestral) are most plausibly implicated and should target cause(s) appropriately.

While there have been improvements in Black-White disparities in several dialysis quality measures (e.g. adequacy, anemia), especially at an individual level, several areas such as RRT options, AVF placement and neighborhood level disparities in dialysis quality measures persist. Strategies such as patient and family level shared decision-making may help patients make more informed decisions about their treatment options for RRT.(127, 128) At the same time we must continue to advocate for the social level changes that can promote equity while ensuring the highest quality of care within our health systems and dialysis facilities. We must advocate for policies that address the social determinants of health coupled with thoughtful assessment of care elements that might be influenced by biology to continue to narrow the Black-White gap in dialysis quality measures and ultimately to achieve health equity and improve outcomes for all patients.

## Acknowledgments

### Funding/Support:

The authors are supported by the research grants from the NIH/NIDDK including K23-DK102903 (CMR), K24-DK091419 (KKZ), P20-MD000182 (KN), UL1TR000124 (KN), P30AG021684 (KN), R01DK098759 (LEB); and philanthropist grants from Mr. Harold Simmons Mr. Louis Chang, Dr. Joseph Lee and AVEO.

## References

1. Nicholas SB, Kalantar-Zadeh K, Norris KC. Racial disparities in kidney disease outcomes. *Seminars in nephrology*. 2013 Sep; 33(5):409–15. Epub 2013/10/15. eng. [PubMed: 24119846]
2. Nicholas SB, Kalantar-Zadeh K, Norris KC. Socioeconomic disparities in chronic kidney disease. *Advances in chronic kidney disease*. 2015 Jan; 22(1):6–15. Epub 2015/01/13. eng. [PubMed: 25573507]

3. USRDS. United States Renal Data System. 2015 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD: 2015. 2015
4. Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. *Journal of the American Society of Nephrology : JASN*. 2003 Nov; 14(11):2902–7. Epub 2003/10/22. eng. [PubMed: 14569100]
5. Powe NR. Let's get serious about racial and ethnic disparities. *Journal of the American Society of Nephrology : JASN*. 2008 Jul; 19(7):1271–5. Epub 2008/06/06. eng. [PubMed: 18524999]
6. Norris K, Nissenson AR. Race, gender, and socioeconomic disparities in CKD in the United States. *Journal of the American Society of Nephrology : JASN*. 2008 Jul; 19(7):1261–70. Epub 2008/06/06. eng. [PubMed: 18525000]
7. Norris KC, Agodoa LY. Unraveling the racial disparities associated with kidney disease. *Kidney international*. 2005 Sep; 68(3):914–24. [PubMed: 16105022]
8. US Department of Health and Human Services. Healthy People 2020: Chronic Kidney Disease. Available at: <https://www.healthypeople.gov/2020/topics-objectives/topic/chronickidney-disease/objectives>
9. Rostand SG, Kirk KA, Rutsky EA, Pate BA. Racial differences in the incidence of treatment for end-stage renal disease. *The New England journal of medicine*. 1982 May 27; 306(21):1276–9. Epub 1982/05/27. eng. [PubMed: 7040967]
10. Dillard MG, Callender CO. End-stage renal disease in blacks: a national or international problem? *Journal of the National Medical Association*. 1984 Dec; 76(12):1157–8. Epub 1984/12/01. Eng. [PubMed: 6512873]
11. Easterling RE. Racial factors in the incidence and causation of end-stage renal disease (ESRD). *Transactions - American Society for Artificial Internal Organs*. 1977; 23:28–33. Epub 1977/01/01. Eng. [PubMed: 910346]
12. Wright JT Jr, Kusek JW, Toto RD, Lee JY, Agodoa LY, Kirk KA, et al. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. *Controlled clinical trials*. 1996 Aug; 17(4 Suppl):3s–16s. Epub 1996/08/01. eng. [PubMed: 8889350]
13. Feldman HI, Klag MJ, Chiappella AP, Whelton PK. End-stage renal disease in US minority groups. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 1992 May; 19(5):397–410. Epub 1992/05/01. eng. [PubMed: 1585925]
14. Norris K, Owen B Jr. Minorities and ESRD: have we seen improvements in care? *Nephrology news & issues*. 1997 Feb; 11(2):66–8. Epub 1997/02/01. eng. [PubMed: 9096475]
15. Reddan DN, Szczech LA, Klassen PS, Owen WF Jr. Racial inequity in America's ESRD program. *Seminars in dialysis*. 2000 Nov-Dec; 13(6):399–403. Epub 2000/12/29. eng. [PubMed: 11130265]
16. Sehgal AR. Impact of quality improvement efforts on race and sex disparities in hemodialysis. *JAMA : the journal of the American Medical Association*. 2003 Feb 26; 289(8):996–1000. Epub 2003/02/25. eng. [PubMed: 12597751]
17. Owen WF Jr, Szczech LA, Frankenfield DL. Healthcare system interventions for inequality in quality: corrective action through evidence-based medicine. *Journal of the National Medical Association*. 2002 Aug; 94(8 Suppl):83s–91s. Epub 2002/08/03. eng. [PubMed: 12152918]
18. Robinson BM, Akizawa T, Jager KJ, Kerr PG, Saran R, Pisoni RL. Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. *Lancet*. 2016 May 20. Epub 2016/05/27. Eng.
19. USRDS. United States Renal Data System. 1994 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD: 1994. 1994
20. Frankenfield DL, Rocco MV, Frederick PR, Pugh J, McClellan WM, Owen WF Jr. Racial/ethnic analysis of selected intermediate outcomes for hemodialysis patients: results from the 1997 ESRD Core Indicators Project. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 1999 Oct; 34(4):721–30. Epub 1999/10/12. eng. [PubMed: 10516355]

21. Frankenfield DL, Marciniak TA, Drass JA, Jencks S. Quality improvement activity directed at the national level: examples from the Health Care Financing Administration. *Quality management in health care*. 1997 Summer;5(4):12–8. Epub 1997/07/01. eng. [PubMed: 10169781]
22. Frederick PR, Frankenfield DL, Biddle MG, Sims TW. Changes in dialysis units' quality improvement practices from 1994 to 1996. *ANNA journal / American Nephrology Nurses' Association*. 1998 Oct; 25(5):469–78. Epub 1999/01/15. eng.
23. Sugarman JR, Frederick PR, Frankenfield DL, Owen WF Jr, McClellan WM. Developing clinical performance measures based on the Dialysis Outcomes Quality Initiative Clinical Practice Guidelines: process, outcomes, and implications. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2003 Oct; 42(4):806–12. Epub 2003/10/02. eng. [PubMed: 14520632]
24. Owen W Jr, Roberts J, Alexander S, Cohen D, Harmon W, Ing T, Kari J, Keen M, King Karren, Letteri J, Lundin AP, Messana A, Nardini J, Norris K, Politoski G, Work Group Members. NKF-DOQI Clinical Practice Guidelines for Hemodialysis Adequacy. *Am J Kidney Dis*. 1997; 30:15S–66S.
25. Turenne MN, Cope EL, Porenta S, Mukhopadhyay P, Fuller DS, Pearson JM, et al. Has dialysis payment reform led to initial racial disparities in anemia and mineral metabolism management? *Journal of the American Society of Nephrology : JASN*. 2015 Mar; 26(3):754–64. Epub 2014/10/11. eng. [PubMed: 25300289]
26. Saunders MR, Chin MH. Variation in dialysis quality measures by facility, neighborhood, and region. *Medical care*. 2013 May; 51(5):413–7. Epub 2013/04/13. eng. [PubMed: 23579351]
27. Hall YN, Xu P, Chertow GM, Himmelfarb J. Characteristics and performance of minority-serving dialysis facilities. *Health services research*. 2014 Jun; 49(3):971–91. Epub 2013/12/21. eng. [PubMed: 24354718]
28. Perry GS, Byers T, Yip R, Margen S. Iron nutrition does not account for the hemoglobin differences between blacks and whites. *The Journal of nutrition*. 1992 Jul; 122(7):1417–24. Epub 1992/07/01. eng. [PubMed: 1619469]
29. McFarlane SI, Chen SC, Whaley-Connell AT, Sowers JR, Vassalotti JA, Salifu MO, et al. Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2008 Apr; 51(4 Suppl 2):S46–55. Epub 2008/04/11. eng. [PubMed: 18359408]
30. Lea JP, Norris K, Agodoa L. The role of anemia management in improving outcomes for African-Americans with chronic kidney disease. *American journal of nephrology*. 2008; 28(5):732–43. [PubMed: 18434712]
31. Derebail VK, Nachman PH, Key NS, Ansede H, Falk RJ, Rosamond WD, et al. Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. *Kidney international*. 2011 Nov; 80(9):992–9. Epub 2011/08/19. eng. [PubMed: 21849972]
32. Beutler E, West C. Hematologic differences between African-Americans and whites: the roles of iron deficiency and alpha-thalassemia on hemoglobin levels and mean corpuscular volume. *Blood*. 2005 Jul 15; 106(2):740–5. Epub 2005/03/26. eng. [PubMed: 15790781]
33. Rattanasompattikul M, Molnar MZ, Zaritsky JJ, Hatamizadeh P, Jing J, Norris KC, et al. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2013 Jul; 28(7):1936–45.
34. Luo J, Jensen DE, Maroni BJ, Brunelli SM. Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2016 Aug 12. Epub 2016/08/17. Eng.
35. Chertow GM, Liu J, Monda KL, Gilbertson DT, Brookhart MA, Beaubrun AC, et al. Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. *Journal of the American Society of Nephrology : JASN*. 2016 Oct; 27(10):3129–38. Epub 2016/02/27. Eng. [PubMed: 26917691]

36. Shen JI, Norris KC. ESRD Payment Reform: First Do No Harm. *Journal of the American Society of Nephrology : JASN*. 2016 Mar 29. Epub 2016/03/31. Eng.
37. Wang C, Kane R, Levenson M, Kelman J, Wernecke M, Lee JY, et al. Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare. *JAMA internal medicine*. 2016 Oct 24. Epub 2016/10/25. Eng.
38. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2003 Oct; 42(4 Suppl 3):S1–201. Epub 2003/10/02. Eng. [PubMed: 14520607]
39. Kalantar-Zadeh K, Miller JE, Kovesdy CP, Mehrotra R, Lukowsky LR, Streja E, et al. Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. 2010 Dec; 25(12):2724–34. Epub 2010/07/09. eng.
40. Jovanovich A, Chonchol M, Cheung AK, Kaufman JS, Greene T, Roberts WL, et al. Racial differences in markers of mineral metabolism in advanced chronic kidney disease. *Clinical journal of the American Society of Nephrology : CJASN*. 2012 Apr; 7(4):640–7. Epub 2012/03/03. Eng. [PubMed: 22383748]
41. Gutierrez OM, Isakova T, Andress DL, Levin A, Wolf M. Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease. *Kidney international*. 2008 Apr; 73(8): 956–62. Epub 2008/02/08. Eng. [PubMed: 18256597]
42. Scialla JJ, Parekh RS, Eustace JA, Astor BC, Plantinga L, Jaar BG, et al. Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis. *American journal of nephrology*. 2015; 42(1):25–34. Epub 2015/08/20. Eng. [PubMed: 26287973]
43. Artaza JN, Contreras S, Garcia LA, Mehrotra R, Gibbons G, Shohet R, et al. Vitamin D and cardiovascular disease: potential role in health disparities. *Journal of health care for the poor and underserved*. 2011; 22(4 Suppl):23–38. [PubMed: 22102304]
44. Stehman-Breen CO, Sherrard D, Walker A, Sadler R, Alem A, Lindberg J. Racial differences in bone mineral density and bone loss among end-stage renal disease patients. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 1999 May; 33(5):941–6. Epub 1999/04/23. Eng. [PubMed: 10213653]
45. Stehman-Breen CO, Sherrard DJ, Alem AM, Gillen DL, Heckbert SR, Wong CS, et al. Risk factors for hip fracture among patients with end-stage renal disease. *Kidney international*. 2000 Nov; 58(5):2200–5. Epub 2000/10/24. eng. [PubMed: 11044242]
46. Arneson TJ, Li S, Liu J, Kilpatrick RD, Newsome BB, St Peter WL. Trends in hip fracture rates in US hemodialysis patients, 1993–2010. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2013 Oct; 62(4):747–54. Epub 2013/05/02. eng. [PubMed: 23631997]
47. Mathew AT, Hazzan A, Jhaveri KD, Block GA, Chidella S, Rosen L, et al. Increasing hip fractures in patients receiving hemodialysis and peritoneal dialysis. *American journal of nephrology*. 2014; 40(5):451–7. Epub 2014/11/28. eng. [PubMed: 25427771]
48. Gupta A, Kallenbach LR, Zasuwa G, Divine GW. Race is a major determinant of secondary hyperparathyroidism in uremic patients. *Journal of the American Society of Nephrology : JASN*. 2000 Feb; 11(2):330–4. Epub 2000/02/09. Eng. [PubMed: 10665940]
49. Wolf M, Betancourt J, Chang Y, Shah A, Teng M, Tamez H, et al. Impact of activated vitamin D and race on survival among hemodialysis patients. *Journal of the American Society of Nephrology : JASN*. 2008 Jul; 19(7):1379–88. [PubMed: 18400938]
50. Patibandla BK, Narra A, Desilva R, Chawla V, Vin Y, Brown RS, et al. Disparities in arteriovenous fistula placement in older hemodialysis patients. *Hemodialysis international International Symposium on Home Hemodialysis*. 2014 Jan; 18(1):118–26. Epub 2013/10/15. eng. [PubMed: 24118883]
51. Hod T, Desilva RN, Patibandla BK, Vin Y, Brown RS, Goldfarb-Rumyantzev AS. Factors predicting failure of AV “fistula first” policy in the elderly. *Hemodialysis international International Symposium on Home Hemodialysis*. 2014 Apr; 18(2):507–15. Epub 2014/01/10. Eng. [PubMed: 24400842]

52. NKF-K III. /DOQI Clinical Practice Guidelines for Vascular Access: Update 2000. *American Journal of Kidney Diseases*. 37(1):S137–S81.
53. Rivara, MB., Mehrotra, R. *Hemodialysis Access*. Springer; 2017. *The Current State of Hemodialysis Access and Dialysis Access Initiatives in the United States*; p. 21-9.
54. Nee R, Moon DS, Jindal RM, Hurst FP, Yuan CM, Agodoa LY, et al. Impact of Poverty and Health Care Insurance on Arteriovenous Fistula Use among Incident Hemodialysis Patients. *American journal of nephrology*. 2015; 42(4):328–36. Epub 2015/11/17. eng. [PubMed: 26569600]
55. Zarkowsky DS, Arhuidese IJ, Hicks CW, Canner JK, Qazi U, Obeid T, et al. Racial/Ethnic Disparities Associated With Initial Hemodialysis Access. *JAMA surgery*. 2015 Apr 29. Epub 2015/04/30. Eng.
56. Sehgal AR, Silver MR, Covinsky KE, Coffin R, Cain JA. Use of standardized ratios to examine variability in hemodialysis vascular access across facilities. Medical Review Board of The Renal Network, Inc. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2000 Feb; 35(2):275–81. Epub 2000/02/17. eng. [PubMed: 10676727]
57. Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS, et al. The timing of specialist evaluation in chronic kidney disease and mortality. *Annals of internal medicine*. 2002 Sep 17; 137(6):479–86. Epub 2002/09/17. eng. [PubMed: 12230348]
58. Gillespie BW, Morgenstern H, Hedgeman E, Tilea A, Scholz N, Shearon T, et al. Nephrology care prior to end-stage renal disease and outcomes among new ESRD patients in the USA. *Clinical kidney journal*. 2015 Dec; 8(6):772–80. Epub 2015/11/28. eng. [PubMed: 26613038]
59. Arora P, Obrador GT, Ruthazer R, Kausz AT, Meyer KB, Jenuleson CS, et al. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. *Journal of the American Society of Nephrology : JASN*. 1999 Jun; 10(6):1281–6. Epub 1999/06/11. eng. [PubMed: 10361866]
60. Prakash S, Rodriguez RA, Austin PC, Saskin R, Fernandez A, Moist LM, et al. Racial composition of residential areas associates with access to pre-ESRD nephrology care. *Journal of the American Society of Nephrology : JASN*. 2010 Jul; 21(7):1192–9. Epub 2010/06/19. eng. [PubMed: 20558541]
61. Ifudu O, Dawood M, Iofel Y, Valcourt JS, Friedman EA. Delayed referral of black, Hispanic, and older patients with chronic renal failure. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 1999 Apr; 33(4):728–33. Epub 1999/04/09. eng. [PubMed: 10196016]
62. Yan G, Cheung AK, Greene T, Yu AJ, Oliver MN, Yu W, et al. Interstate Variation in Receipt of Nephrologist Care in US Patients Approaching ESRD: Race, Age, and State Characteristics. *Clinical journal of the American Society of Nephrology : CJASN*. 2015 Nov 6; 10(11):1979–88. Epub 2015/10/10. eng. [PubMed: 26450930]
63. Boulware LE, Cooper LA, Ratner LE, LaVeist TA, Powe NR. Race and trust in the health care system. *Public health reports (Washington, DC: 1974)*. 2003 Jul-Aug; 118(4):358–65. Epub 2003/06/20. eng.
64. Norton JM, Moxey-Mims MM, Eggers PW, Narva AS, Star RA, Kimmel PL, et al. Social Determinants of Racial Disparities in CKD. *Journal of the American Society of Nephrology : JASN*. 2016 Sep; 27(9):2576–95. Epub 2016/05/15. Eng. [PubMed: 27178804]
65. Narva AS, Norton JM, Boulware LE. Educating Patients about CKD: The Path to Self-Management and Patient-Centered Care. *Clinical journal of the American Society of Nephrology : CJASN*. 2016 Apr 07; 11(4):694–703. Epub 2015/11/06. eng. [PubMed: 26536899]
66. Kalantar-Zadeh K, Kovesdy CP, Derose SF, Horwich TB, Fonarow GC. Racial and survival paradoxes in chronic kidney disease. *Nature clinical practice Nephrology*. 2007 Sep; 3(9):493–506. Epub 2007/08/25. eng.
67. Rhee CM, Lertdumrongluk P, Streja E, Park J, Moradi H, Lau WL, et al. Impact of age, race and ethnicity on dialysis patient survival and kidney transplantation disparities. *American journal of nephrology*. 2014; 39(3):183–94. Epub 2014/02/22. eng. [PubMed: 24556752]
68. Yan G, Norris KC, Yu AJ, Ma JZ, Greene T, Yu W, et al. The relationship of age, race, and ethnicity with survival in dialysis patients. *Clinical journal of the American Society of Nephrology : CJASN*. 2013 Jun; 8(6):953–61. [PubMed: 23539227]




69. Kalantar-Zadeh K, Kovesdy CP, Norris KC. Racial survival paradox of dialysis patients: robust and resilient. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2012 Aug; 60(2):182–5. [PubMed: 22495468]
70. Kucirka LM, Grams ME, Lessler J, Hall EC, James N, Massie AB, et al. Association of race and age with survival among patients undergoing dialysis. *JAMA : the journal of the American Medical Association*. 2011 Aug 10; 306(6):620–6. Epub 2011/08/11. eng. [PubMed: 21828325]
71. Kalantar-Zadeh K, Golan E, Shohat T, Streja E, Norris KC, Kopple JD. Survival disparities within American and Israeli dialysis populations: learning from similarities and distinctions across race and ethnicity. *Seminars in dialysis*. 2010 Nov-Dec;23(6):586–94. [PubMed: 21175833]
72. Rhee CM, Kalantar-Zadeh K, Norris KC. Why minorities live longer on dialysis: an in-depth examination of the Danish nephrology registry. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2016 Jan 6. Epub 2016/01/09. Eng.
73. van den Beukel TO, Hommel K, Kamper AL, Heaf JG, Siegert CE, Honig A, et al. Differences in survival on chronic dialysis treatment between ethnic groups in Denmark: a population-wide, national cohort study. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2016 Jul; 31(7):1160–7. Epub 2015/10/24. eng.
74. Arce CM, Goldstein BA, Mitani AA, Winkelmayr WC. Trends in relative mortality between Hispanic and non-Hispanic whites initiating dialysis: a retrospective study of the US Renal Data System. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2013 Aug; 62(2):312–21. Epub 2013/05/08. eng. [PubMed: 23647836]
75. Pei YP, Greenwood CM, Chery AL, Wu GG. Racial differences in survival of patients on dialysis. *Kidney Int*. 2000 Sep; 58(3):1293–9. Epub 2000/09/06. eng. [PubMed: 10972693]
76. Rhee CM, Kalantar-Zadeh K, Norris KC. Why minorities live longer on dialysis: an in-depth examination of the Danish nephrology registry. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2016 Jul; 31(7):1027–30. Epub 2016/01/09. Eng.
77. Kalbfleisch J, Wolfe R, Bell S, Sun R, Messana J, Shearon T, et al. Risk Adjustment and the Assessment of Disparities in Dialysis Mortality Outcomes. *Journal of the American Society of Nephrology : JASN*. 2015 Nov; 26(11):2641–5. Epub 2015/04/18. eng. [PubMed: 25882829]
78. Rodriguez RA, Sen S, Mehta K, Moody-Ayers S, Bacchetti P, O'Hare AM. Geography matters: relationships among urban residential segregation, dialysis facilities, and patient outcomes. *Annals of internal medicine*. 2007 Apr 3; 146(7):493–501. Epub 2007/04/04. eng. [PubMed: 17404351]
79. Zhang Y. The Association Between Dialysis Facility Quality and Facility Characteristics, Neighborhood Demographics, and Region. *American journal of medical quality : the official journal of the American College of Medical Quality*. 2016 Jul; 31(4):358–63. Epub 2015/04/04. eng. [PubMed: 25838553]
80. Kovesdy CP, Norris KC, Boulware LE, Lu JL, Ma JZ, Streja E, et al. Association of Race With Mortality and Cardiovascular Events in a Large Cohort of US Veterans. *Circulation*. 2015 Oct 20; 132(16):1538–48. Epub 2015/09/20. eng. [PubMed: 26384521]
81. Norris KC, Mensah GA, Boulware LE, Lu JL, Ma JZ, Streja E, et al. Age, Race and Cardiovascular Outcomes in African American Veterans. *Ethnicity & disease*. 2016 Summer; 26(3):305–14. Epub 2016/07/22. eng. [PubMed: 27440969]
82. Marshall E. DNA studies challenge the meaning of race. *Science (New York, NY)*. 1998 Oct 23; 282(5389):654–5. Epub 1998/12/05. eng.
83. Collins FS. What we do and don't know about 'race', 'ethnicity', genetics and health at the dawn of the genome era. *Nature genetics*. 2004 Nov; 36(11 Suppl):S13–5. Epub 2004/10/28. eng. [PubMed: 15507997]
84. Stuurman, S., editor. *History Workshop Journal*. Oxford Univ Press; 2000. François Bernier and the invention of racial classification.
85. Harawa NT, Ford CL. The foundation of modern racial categories and implications for research on black/white disparities in health. *Ethnicity & disease*. 2009 Spring;19(2):209–17. Epub 2009/06/20. eng. [PubMed: 19537235]

86. Webster, M., Webster, M. Dictionary Retrieved from Merriam-Webster. 2016. Online: <http://www.merriam-webster.com/dictionary/process>
87. Directive OS. 15. Standards for maintaining, collecting, and presenting federal data on race and ethnicity. Federal Register. 1997; 30
88. Registrar F. Revisions to the standards for the classification of federal data on race and ethnicity. Federal Register. 1997; 62:58781–90.
89. Pew Research Center. What Census Calls Us: A Historical Timeline. 2015. Accessed 10-2-16 at <http://www.pewsocialtrends.org/interactives/multiracial-timeline/>
90. Harawa NT, Norris KC. The Role of Ethnic Variation and CKD. Clinical journal of the American Society of Nephrology : CJASN. 2015 Oct 7; 10(10):1708–10. Epub 2015/09/30. Eng. [PubMed: 26416945]
91. Ford CL, Harawa NT. A new conceptualization of ethnicity for social epidemiologic and health equity research. Social science & medicine (1982). 2010 Jul; 71(2):251–8. Epub 2010/05/22. eng. [PubMed: 20488602]
92. Bruce MA, Beech BM, Sims M, Brown TN, Wyatt SB, Taylor HA, et al. Social environmental stressors, psychological factors, and kidney disease. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2009 Apr; 57(4):583–9. Epub 2009/02/26. eng. [PubMed: 19240646]
93. De La Cruz-Viesca, M., Chen, Z., Ong, PM., Hamilton, D., William, AD, Jr. The Color of Wealth in Los Angeles. Report produced by Duke University, The New School, and University of California; Los Angeles: 2016.
94. Plantinga LC, Johansen KL, Schillinger D, Powe NR. Lower socioeconomic status and disability among US adults with chronic kidney disease, 1999–2008. Preventing chronic disease. 2012; 9:E12. Epub 2011/12/17. eng. [PubMed: 22172179]
95. Choi AI, Weekley CC, Chen SC, Li S, Tamura MK, Norris KC, et al. Association of educational attainment with chronic disease and mortality: the Kidney Early Evaluation Program (KEEP). American journal of kidney diseases : the official journal of the National Kidney Foundation. 2011 Aug; 58(2):228–34. Epub 2011/05/24. eng. [PubMed: 21601328]
96. Young BA. The interaction of race, poverty, and CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2010 Jun; 55(6):977–80. Epub 2010/05/26. eng. [PubMed: 20497834]
97. Mode NA, Evans MK, Zonderman AB. Race, Neighborhood Economic Status, Income Inequality and Mortality. PloS one. 2016; 11(5):e0154535. Epub 2016/05/14. eng. [PubMed: 27171406]
98. Kimmel PL, Fwu CW, Eggers PW. Segregation, income disparities, and survival in hemodialysis patients. Journal of the American Society of Nephrology : JASN. 2013 Feb; 24(2):293–301. Epub 2013/01/22. eng. [PubMed: 23334394]
99. Crews DC, Liu Y, Boulware LE. Disparities in the burden, outcomes, and care of chronic kidney disease. Current opinion in nephrology and hypertension. 2014 May; 23(3):298–305. Epub 2014/03/26. eng. [PubMed: 24662984]
100. World Health Organization. A conceptual framework for action on the social determinants of health. 2010
101. Abdou CM, Fingerhut AW, Jackson JS, Wheaton F. Healthcare Stereotype Threat in Older Adults in the Health and Retirement Study. American journal of preventive medicine. 2016 Feb; 50(2): 191–8. Epub 2015/10/27. Eng. [PubMed: 26497263]
102. Wing MR, Devaney JM, Joffe MM, Xie D, Feldman HI, Dominic EA, et al. DNA methylation profile associated with rapid decline in kidney function: findings from the CRIC study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2014 Apr; 29(4):864–72. Epub 2014/02/12. eng.
103. Laster M, Norris KC. Lessons Learned in Mortality and Kidney Transplant Outcomes Among Pediatric Dialysis Patients. J Am Soc Nephrol. 2017 (in press).
104. Joshi S, Gaynor JJ, Bayers S, Guerra G, Eldefrawy A, Chediak Z, et al. Disparities among Blacks, Hispanics, and Whites in time from starting dialysis to kidney transplant waitlisting. Transplantation. 2013 Jan 27; 95(2):309–18. Epub 2013/01/18. eng. [PubMed: 23325005]

105. Saunders MR, Lee H, Alexander GC, Tak HJ, Thistlethwaite JR Jr, Ross LF. Racial disparities in reaching the renal transplant waitlist: is geography as important as race? *Clinical transplantation*. 2015 Jun; 29(6):531–8. Epub 2015/03/31. eng. [PubMed: 25818547]
106. Mehrotra R, Soohoo M, Rivara MB, Himmelfarb J, Cheung AK, Arah OA, et al. Racial and Ethnic Disparities in Use of and Outcomes with Home Dialysis in the United States. *Journal of the American Society of Nephrology : JASN*. 2016 Jul; 27(7):2123–34. Epub 2015/12/15. Eng. [PubMed: 26657565]
107. Smedley, BD., Stith, AY., Nelson, AR. Unequal treatment: confronting racial and ethnic disparities in health care (with CD). National Academies Press; 2009.
108. Naik RP, Derebail VK, Grams ME, Franceschini N, Auer PL, Peloso GM, et al. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. *JAMA : the journal of the American Medical Association*. 2014 Nov 26; 312(20):2115–25. Epub 2014/11/14. eng. [PubMed: 25393378]
109. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. *Science (New York, NY)*. 2010 Aug 13; 329(5993):841–5. Epub 2010/07/22. eng.
110. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, et al. APOL1 Risk Variants, Race, and Progression of Chronic Kidney Disease. *The New England journal of medicine*. 2013 Nov 9. Epub 2013/11/12. Eng.
111. Bodonyi-Kovacs G, Ma JZ, Lipkowitz MS, Kopp JB, Winkler CA, Le TH. Combined Effects of GSTM1 Null Allele and APOL1 Renal Risk Alleles in CKD Progression in the African American Study of Kidney Disease and Hypertension Trial. *Journal of the American Society of Nephrology : JASN*. 2016 Mar 3. Epub 2016/03/05. Eng.
112. Willcox BJ, Tranah GJ, Chen R, Morris BJ, Masaki KH, He Q, et al. The FoxO3 gene and cause-specific mortality. *Aging cell*. 2016 Apr 13. Epub 2016/04/14. Eng.
113. Powe CE, Karumanchi SA, Thadhani R. Vitamin D-binding protein and vitamin D in blacks and whites. *The New England journal of medicine*. 2014 Feb 27; 370(9):880–1. Epub 2014/02/28. eng. [PubMed: 24571762]
114. Palmer ND, Divers J, Lu L, Register TC, Carr JJ, Hicks PJ, et al. Admixture mapping of serum vitamin D and parathyroid hormone concentrations in the African American-Diabetes Heart Study. *Bone*. 2016 Jun.87:71–7. Epub 2016/04/02. Eng. [PubMed: 27032714]
115. Chen YW, Wu YT, Lin JS, Yang WC, Hsu YH, Lee KH, et al. Association of Genetic Polymorphisms of Renin-Angiotensin-Aldosterone System-Related Genes with Arterio-Venous Fistula Malfunction in Hemodialysis Patients. *International journal of molecular sciences*. 2016 May 27.17(6) Epub 2016/05/31. Eng.
116. Reddan D, Klassen P, Frankenfield DL, Szczech L, Schwab S, Coladonato J, et al. National profile of practice patterns for hemodialysis vascular access in the United States. *Journal of the American Society of Nephrology : JASN*. 2002 Aug; 13(8):2117–24. Epub 2002/07/26. eng. [PubMed: 12138144]
117. Norris KC, Kalantar-Zadeh K, Kopple JD. The role of race in survival among patients undergoing dialysis. *Nephrology news & issues*. 2011 Dec; 25(13):13–4. 6.
118. Myers HF. Ethnicity- and socio-economic status-related stresses in context: an integrative review and conceptual model. *Journal of behavioral medicine*. 2009 Feb; 32(1):9–19. Epub 2008/11/08. eng. [PubMed: 18989769]
119. Ulbrich PM, Warheit GJ, Zimmerman RS. Race, socioeconomic status, and psychological distress: An examination of differential vulnerability. *Journal of Health and Social Behavior*. 1989:131–46. [PubMed: 2723379]
120. Johns TS, Estrella MM, Crews DC, Appel LJ, Anderson CA, Ephraim PL, et al. Neighborhood socioeconomic status, race, and mortality in young adult dialysis patients. *Journal of the American Society of Nephrology : JASN*. 2014 Nov; 25(11):2649–57. Epub 2014/06/14. eng. [PubMed: 24925723]
121. Norris KC. On Race and Medicine: until health care becomes truly personalized, race and ethnicity will continue to be important clues guiding medical treatments. *The Scientist*. Febuary;

2014 28(2) <http://www.the-scientist.com/?articles.view/articleNo/38950/title/On-Race-and-Medicine/>.

122. Williams AW. Health policy, disparities, and the kidney. *Advances in chronic kidney disease*. 2015 Jan; 22(1):54–9. Epub 2015/01/13. eng. [PubMed: 25573513]
123. Koh HK. Improving Health and Health Care in the United States: Toward a State of Complete Well-being. *JAMA : the journal of the American Medical Association*. 2016 Oct 25; 316(16): 1679–81. Epub 2016/10/27. Eng. [PubMed: 27669540]
124. Centers for M, Medicaid Services HHS. Medicare Program; End-Stage Renal Disease Prospective Payment System, and Quality Incentive Program. Final Rule. *Fed Regist*. 2015 Nov 6; 80(215): 68967–9077. Epub 2015/11/11. eng. [PubMed: 26552112]
125. Nissenson AR, Mayne TJ, Krishnan M. The 2009 proposed rule for prospective ESRD payment: perspectives from a large dialysis organization. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2010 Feb; 55(2):223–6. Epub 2010/02/02. eng. [PubMed: 20116683]
126. Roach JL, Turenne MN, Hirth RA, Wheeler JR, Sleeman KS, Messana JM. Using race as a case-mix adjustment factor in a renal dialysis payment system: potential and pitfalls. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2010 Nov; 56(5): 928–36. Epub 2010/10/05. eng. [PubMed: 20888100]
127. Ameling JM, Auguste P, Ephraim PL, Lewis-Boyer L, DePasquale N, Greer RC, et al. Development of a decision aid to inform patients' and families' renal replacement therapy selection decisions. *BMC medical informatics and decision making*. 2012 Dec 01.12:140. Epub 2012/12/04. eng. [PubMed: 23198793]
128. Sheu J, Ephraim PL, Powe NR, Rabb H, Senga M, Evans KE, et al. African American and non-African American patients' and families' decision making about renal replacement therapies. *Qualitative health research*. 2012 Jul; 22(7):997–1006. Epub 2012/05/31. eng. [PubMed: 22645225]



**Figure 1.** Interconnections between race/ethnicity and health status. Adapted by permission from Macmillan Publishers Ltd: *Nature Genetics* 36(11 Suppl):S13–5, copyright (2004).(83)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 1**

Summary of existing state of Black-White Disparities for Patients treated with Dialysis

<b>Key Dialysis Measures of Interest</b>	<b>Black-White Disparity</b>
Renal Replacement Therapy Modality Options	Black patients are less likely to be treated with peritoneal dialysis, home hemodialysis, transplantation or palliative care
Dialysis Adequacy	Black patients now have similar levels of dialysis adequacy, but facilities in neighborhoods with high numbers of Blacks have worse measures of dialysis adequacy
Anemia	Black patients now have similar levels of anemia while they require higher doses of erythropoietin stimulating agents. Facilities in neighborhoods with high numbers of Blacks have worse measures of anemia
Mineral And Bone Disease	Black patients now have similar levels of mineral and bone disease measures they require higher doses of activated Vitamin D and cinacalcet. Facilities in neighborhoods with high numbers of Blacks have worse measures of mineral and bone disease
Vascular Access	Black patients are less likely to receive placement of an arteriovenous fistula prior to first ESRD dialysis treatment
Pre-End-Stage Renal Disease Care	Black patients are less likely to receive pre-ESRD nephrology care
Survival in Dialysis	Black patients are more likely to survive on dialysis despite suffering from lower rates of several markers of quality dialysis care.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 2**

Summary of key dialysis measures and the corresponding potential socioecologic and biologic determinants

Key Dialysis Measures of Interest	Potential Socio-Ecologic Determinants	Potential Biologic Determinants
ESRD Incidence	<ul style="list-style-type: none"> <li>- Limited insurance status and low SES, limited family and health care resources, patient medical mistrust, healthcare health beliefs and behaviors, stereotype threat,</li> <li>- Unconscious provider bias</li> <li>- Health system barriers</li> <li>- Poor control of ESRD medical risk factors</li> <li>- Excess exposure to environmental toxins</li> </ul>	Increased prevalence of sickle cell disease/trait, APOL1 CKD risk alleles and other (e.g. epigenetic changes)
RRT Modality Options	<ul style="list-style-type: none"> <li>- Limited insurance status and low SES, limited family and health care resources, patient medical mistrust, healthcare health beliefs and behaviors, stereotype threat</li> <li>- Unconscious provider bias</li> <li>- Health system barriers</li> </ul>	Unlikely
Vascular Access	Insurance status (especially pre-ESRD), health beliefs and behaviors	Possible differences in vessel size and structure, higher ESA dosing may adversely affect fistula maturation
Dialysis Adequacy	Unconscious bias, health beliefs and behaviors	Unlikely
Anemia	Insurance status to pay for iron and erythropoietin stimulating agent therapies	Increased prevalence of variant hemoglobins (Lower mean hemoglobin in general population)
Mineral And Bone Disease	Insurance status to pay for phosphate binders and activated Vitamin D therapies	Increased prevalence of select vitamin D binding protein polymorphism and other (Lower mean 25(OH)D and disproportionately higher intact parathyroid hormone levels in general population)
Pre-ESRD Care	Unconscious bias, medical mistrust, insurance status (especially pre-ESRD), health system barriers, health beliefs and behaviors, healthcare stereotype threat	Unlikely
Survival in Dialysis	Psychosocial resilience	Permissive or effect-modifying biologic related resilience (e.g. protective polymorphisms for stress [glutathione-S-transferase-m1] or survival [FoxO3 gene])